Product Datasheet

CD79A Antibody (IGA/1406) [Alexa Fluor® 750] NBP2-54370AF750

Unit Size: 0.1 ml

Store at 4C in the dark.

www.novusbio.com



technical@novusbio.com

Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NBP2-54370AF750

Updated 10/23/2024 v.20.1

Earn rewards for product reviews and publications.

Submit a publication at www.novusbio.com/publications
Submit a review at www.novusbio.com/reviews/destination/NBP2-54370AF750



NBP2-54370AF750

CD79A Antibody (IGA/1406) [Alexa Fluor® 750]

found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in som myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after	CD/9A Antibody (IGA/1400) [Alexa Fidol® /30]		
Please see the vial label for concentration. If unlisted please contact technical services.	Product Information		
Storage Store at 4C in the dark. Clonality Monoclonal Clone IGA/1406 Preservative 0.05% Sodium Azide Isotype IgG3 Kappa Conjugate Alexa Fluor 750 Purity Protein A or G purified Buffer 50mM Sodium Borate Product Description Host Mouse Gene ID 973 Gene Symbol CD79A Species Human Marker B-Cell Marker Specificity/Sensitivity A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Agreeptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in som myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphomas all male and occasionally some types of endothelial cells as well. Immunogen A synthetic peptide corresponding to aa 202-216 (GTYQDVGSLNIADVQ) of	Unit Size	0.1 ml	
Clonality Monoclonal Clone IGA/1406 Preservative 0.05% Sodium Azide Isotype IgG3 Kappa Conjugate Alexa Fluor 750 Purity Protein A or G purified Buffer 50mM Sodium Borate Product Description Host Mouse Gene ID 973 Gene Symbol CD79A Species Human Marker B-Cell Marker Specificity/Sensitivity A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in som myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well. Immunogen A synthetic peptide corresponding to aa 202-216 (GTYQDVGSLNIADVQ) of	Concentration	·	
Clone IGA/1406 Preservative 0.05% Sodium Azide IgG3 Kappa Conjugate Alexa Fluor 750 Purity Protein A or G purified Buffer 50mM Sodium Borate Product Description Host Gene ID 973 Gene Symbol CD79A Species Human Marker B-Cell Marker Specificity/Sensitivity A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lymphomas, and in som myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well. Immunogen A synthetic peptide corresponding to aa 202-216 (GTYQDVGSLNIADVQ) of	Storage	Store at 4C in the dark.	
Preservative 1gG3 Kappa 1gG3 Kappa 1gG3 Kappa 2Gnjugate 2Gnjugate	Clonality	Monoclonal	
IgG3 Kappa	Clone	IGA/1406	
Conjugate Alexa Fluor 750 Purity Protein A or G purified Buffer 50mM Sodium Borate Product Description Host Mouse Gene ID 973 Gene Symbol CD79A Species Human Marker B-Cell Marker Specificity/Sensitivity A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulins constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in som myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphoma/leukemia than is anti-CD20. Anti-CD79a is so stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well. Immunogen A synthetic peptide corresponding to aa 202-216 (GTYQDVGSLNIADVQ) of	Preservative	0.05% Sodium Azide	
Protein A or G purified Buffer 50mM Sodium Borate Product Description Host Mouse Gene ID 973 Gene Symbol CD79A Species Human Marker B-Cell Marker Specificity/Sensitivity A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in som myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas as after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well. Immunogen A synthetic peptide corresponding to aa 202-216 (GTYQDVGSLNIADVQ) of	Isotype	IgG3 Kappa	
Buffer 50mM Sodium Borate	Conjugate	Alexa Fluor 750	
Product Description Host Mouse Gene ID 973 Gene Symbol CD79A Species Human Marker B-Cell Marker Specificity/Sensitivity A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in som myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well. Immunogen A synthetic peptide corresponding to aa 202-216 (GTYQDVGSLNIADVQ) of	Purity	Protein A or G purified	
Host Gene ID 973 Gene Symbol CD79A Species Human Marker B-Cell Marker Specificity/Sensitivity A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in som myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well. Immunogen Marker B-Cell Marker A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79a) is deported by and B29 (or CD79a) is deported by and B29 (or CD79a) is generally used to complement anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.	Buffer	50mM Sodium Borate	
Gene Symbol CD79A Species Human Marker B-Cell Marker Specificity/Sensitivity A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in som myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well. Immunogen A synthetic peptide corresponding to aa 202-216 (GTYQDVGSLNIADVQ) of	Product Description		
Gene Symbol CD79A Species Human B-Cell Marker B-Cell Marker Specificity/Sensitivity A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in som myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well. Immunogen A synthetic peptide corresponding to aa 202-216 (GTYQDVGSLNIADVQ) of	Host	Mouse	
Species Human	Gene ID	973	
Marker B-Cell Marker A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in som myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well. Immunogen A synthetic peptide corresponding to aa 202-216 (GTYQDVGSLNIADVQ) of	Gene Symbol	CD79A	
A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in som myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well. Immunogen A synthetic peptide corresponding to aa 202-216 (GTYQDVGSLNIADVQ) of	Species	Human	
CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in som myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well. Immunogen A synthetic peptide corresponding to aa 202-216 (GTYQDVGSLNIADVQ) of	Marker	B-Cell Marker	
	Specificity/Sensitivity	CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of	
	Immunogen		



Page 2 of 3 v.20.1 Updated 10/23/2024	
Notes	Alexa Fluor (R) products are provided under an intellectual property license from Life Technologies Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: (i) in manufacturing; (ii) to provide a service, information, or data in return for payment; (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com. This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.
Product Application Details	
Applications	Western Blot, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, CyTOF-ready

CyTOF-ready

Western Blot, Flow Cytometry, Immunocytochemistry/ Immunofluorescence,

Optimal dilution of this antibody should be experimentally determined.

Recommended Dilutions

Application Notes



Novus Biologicals USA

10730 E. Briarwood Avenue Centennial, CO 80112

USA

Phone: 303.730.1950 Toll Free: 1.888.506.6887

Fax: 303.730.1966

nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave Toronto, ON M8Z 4E6

Canada

Phone: 905.827.6400 Toll Free: 855.668.8722 Fax: 905.827.6402

canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane Abingdon Science Park Abingdon, OX14 3NB, United Kingdom Phone: (44) (0) 1235 529449

Free Phone: 0800 37 34 15 Fax: (44) (0) 1235 533420 info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com

Technical Support: nb-technical@bio-

techne.com

Orders: nb-customerservice@bio-techne.com

General: novus@novusbio.com

Products Related to NBP2-54370AF750

NBP2-60209-50ug Recombinant Human CD79A His Protein

7268-CT-100 CTLA-4 [Unconjugated] 9685-CD-050 CD79A [Unconjugated]

AF114 CD45 Antibody [Unconjugated]

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP2-54370AF750

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications

